指南与共识炎症性肠病胃肠动力与功能性疾病

AGA临床实践更新:炎症性肠病患者功能性胃肠症状的专家评审

AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2018-08-09

本AGA临床实践更新基于相关科学文献、系统综述及专家意见,提出14条最佳实践建议,阐述炎症性肠病患者功能性胃肠症状的诊断与管理原则,涵盖排除活动性炎症的阶梯式方法、饮食与心理治疗、药物选择及益生菌等。

要点

  • 对持续胃肠症状的炎症性肠病患者,应阶梯式排除活动性炎症,包括粪钙卫蛋白、内镜活检及横断面影像。
  • 粪钙卫蛋白不确定且症状轻微者可考虑系列监测;有梗阻症状者应考虑解剖异常或结构并发症。
  • 低FODMAP饮食可提供但需注意营养充足;心理治疗应考虑;益生菌可考虑;粪菌移植及补充替代疗法在进一步证据前不应提供。

核心结论

  • 本临床实践更新提出14条最佳实践建议,以指导炎症性肠病患者功能性胃肠症状的诊断与管理。

研究设计与样本

  • 本临床实践更新由AGA研究所制作,证据与最佳实践基于相关科学文献、系统综述及适用的专家意见。

主要发现

  • 最佳实践建议1:对持续胃肠症状的炎症性肠病患者,应遵循阶梯式方法排除持续炎症活动,包括测量粪钙卫蛋白、内镜活检及横断面影像。
  • 最佳实践建议2:对粪钙卫蛋白水平不确定且症状轻微的患者,临床医生可考虑系列钙卫蛋白监测以促进预期性管理。
  • 最佳实践建议3:对有梗阻症状(包括腹胀、疼痛、恶心呕吐、便秘或无排便)的患者,应考虑解剖异常或结构并发症。
  • 最佳实践建议4:应根据主要症状模式考虑并评估替代病理生理机制,包括小肠细菌过度生长、胆汁酸性腹泻、碳水化合物不耐受、慢性胰腺炎。
  • 最佳实践建议5:可提供低FODMAP饮食用于管理炎症性肠病患者的功能性胃肠症状,同时仔细关注营养充足性。

关键数值与推荐

  • 最佳实践建议6:对伴有功能性症状的炎症性肠病患者,应考虑心理治疗(认知行为疗法、催眠疗法、正念疗法)。
  • 最佳实践建议7:对慢性便秘的炎症性肠病患者,应提供渗透性和刺激性泻药。
  • 最佳实践建议8:对静止期炎症性肠病患者的慢性腹泻,可使用动力抑制药或胆汁酸螯合剂。
  • 最佳实践建议9:对炎症性肠病患者的功能性疼痛,应使用解痉药、神经病理性靶向药物和抗抑郁药,同时应避免使用阿片类药物。
  • 最佳实践建议10:益生菌可考虑用于治疗炎症性肠病患者的功能性症状。

临床怎么用

  • 最佳实践建议11:对存在潜在排便障碍证据的炎症性肠病患者,应提供盆底治疗。
  • 最佳实践建议12:在进一步证据可用之前,不应提供粪菌移植用于治疗炎症性肠病患者的功能性胃肠症状。
  • 最佳实践建议13:应鼓励有功能性胃肠症状的炎症性肠病患者进行体育锻炼。
  • 最佳实践建议14:在进一步证据可用之前,不应常规提供补充和替代疗法用于炎症性肠病患者的功能性症状。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: The purpose of this clinical practice update review is to describe key principles in the diagnosis and management of functional gastrointestinal (GI) symptoms in patients with inflammatory bowel disease (IBD). METHODS: The evidence and best practices summarized in this manuscript are based on relevant scientific publications, systematic reviews, and expert opinion where applicable. Best practice advice 1: A stepwise approach to rule-out ongoing inflammatory activity should be followed in IBD patients with persistent GI symptoms (measurement of fecal calprotectin, endoscopy with biopsy, cross-sectional imaging). Best practice advice 2: In those patients with indeterminate fecal calprotectin levels and mild symptoms, clinicians may consider serial calprotectin monitoring to facilitate anticipatory management. Best practice advice 3: Anatomic abnormalities or structural complications should be considered in patients with obstructive symptoms including abdominal distention, pain, nausea and vomiting, obstipation or constipation. Best practice advice 4: Alternative pathophysiologic mechanisms should be considered and evaluated (small intestinal bacterial overgrowth, bile acid diarrhea, carbohydrate intolerance, chronic pancreatitis) based on predominant symptom patterns. Best practice advice 5: A low FODMAP diet may be offered for management of functional GI symptoms in IBD with careful attention to nutritional adequacy. Best practice advice 6: Psychological therapies (cognitive behavioural therapy, hypnotherapy, mindfulness therapy) should be considered in IBD patients with functional symptoms. Best practice advice 7: Osmotic and stimulant laxative should be offered to IBD patients with chronic constipation. Best practice advice 8: Hypomotility agents or bile-acid sequestrants may be used for chronic diarrhea in quiescent IBD. Best practice advice 9: Antispasmodics, neuropathic-directed agents, and anti-depressants should be used for functional pain in IBD while use of opiates should be avoided. Best practice advice 10: Probiotics may be considered for treatment of functional symptoms in IBD. Best practice advice 11: Pelvic floor therapy should be offered to IBD patients with evidence of an underlying defecatory disorder. Best practice advice 12: Until further evidence is available, fecal microbiota transplant should not be offered for treatment of functional GI symptoms in IBD. Best practice advice 13: Physical exercise should be encourage in IBD patients with functional GI symptoms. Best practice advice 14: Until further evidence is available, complementary and alternative therapies should not be routinely offered for functional symptoms in IBD. This Clinical Practice Update was produced by the AGA Institute.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Colombel JF, Shin A, Gibson PR, et al. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clin Gastroenterol Hepatol. 2018. PMID: 30099108. doi:10.1016/j.cgh.2018.08.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。